Cilostazol for Stroke Recurrence in Cerebral Small Vessel Disease

Phase 4, randomised, open-label trial of cilostazol in Cerebral Small Vessel Disease (CSVD) (2 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoint: Incidence of composite events including new-onset ischemic stroke, transient ischemic attack, cognitive impairment, functional disability, and death at Day 360. Planned start Sep 2025; status: not yet recruiting.